Posts

Posted on

ARDT CLASS REMINDER: Ardent Health, Inc. Class Action Deadline March 9 – Investors Notified to Contact BFA Law about its Filed Lawsuit to Protect Your Rights

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that it has filed a class action lawsuit against Ardent Health, Inc. (NYSE:ARDT) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Ardent Health, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ardent-health-inc-class-action-lawsuit.

Investors have until March 9, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Ardent Health securities. The class action is pending in the U.S. District Court for the Middle District of Tennessee. It is captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022.

Why is Ardent Health Being Sued for Securities Fraud?

Ardent Health and its affiliates operate acute care hospitals and other healthcare facilities. A critical aspect of Ardent Health’s operations is the collection of accounts receivable and the framework by which Ardent Health determines the collectability of such accounts. According to the lawsuit, Ardent Health stated that it employed an active monitoring process to determine the collectability of its accounts receivable, and that this process included “detailed reviews of historical collections” as a “primary source of information.” 

As alleged, in truth, Ardent Health did not primarily rely on “detailed reviews of historical collections” in determining collectability of accounts receivable, but instead “utilized a 180-day cliff at which time an account became fully reserved.” This allowed Ardent Health to report higher amounts of accounts receivable during the Class Period, and delay recognizing losses on uncollectable accounts. The lawsuit alleges that Ardent Health’s purported misrepresentations are a violation of the federal securities laws.

Why did Ardent Health’s Stock Drop?

On November 12, 2025, after market hours, Ardent Health revealed it had completed “hindsight evaluations of historical collection trends” that resulted in a $43 million decrease in revenue for the quarter. Ardent Health also revealed that it increased its professional liability reserves by $54 million because of “adverse prior period claim developments” resulting from a set of claims between 2019 and 2022 “as well as consideration of broader industry trends.”

This news caused the price of Ardent Health stock to drop $4.75 per share, or more than 33%, from a closing price of $14.05 per share on November 12, 2025, to $9.30 per share on November 13, 2025.

Click here for more information:

https://www.bfalaw.com/cases/ardent-health-inc-class-action-lawsuit

.

What Can You Do?

If you invested in Ardent Health, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases/ardent-health-inc-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases/ardent-health-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

FedEx Announces Board of Directors for Future Independent FedEx Freight

FedEx Announces Board of Directors for Future Independent FedEx Freight

Board includes veteran leaders with transportation and logistics, financial, and technology expertise

MEMPHIS, Tenn.–(BUSINESS WIRE)–
FedEx Corp. (NYSE: FDX) today announced the ten-member board of directors for FedEx Freight, ahead of its planned spin-off from FedEx Corp. on June 1, 2026.

As previously announced, R. Brad Martin, current executive chairman of the FedEx Corp. board of directors, will serve as chairman of the board of FedEx Freight. John Smith, the incoming president and chief executive officer of FedEx Freight, will also serve as a director, alongside eight other highly experienced leaders across the transportation and logistics, supply chain management, and technology sectors.

“We’ve assembled a group of prominent industry leaders who share a strong commitment to the customer-first culture that defines FedEx,” said Brad Martin. “Their diverse perspectives and proven leadership will be instrumental in supporting FedEx Freight as it executes a focused strategy and builds on its position as the largest North American LTL freight carrier with industry-leading transit times, service levels, and reliability.”

“I look forward to working with our incoming directors upon completion of the spin-off, leveraging their experience and perspectives, while continuing to partner with Brad and our leadership team as we progress toward launching a world-class, independent organization,” said John Smith.

Biographical Information

The FedEx Freight board will include the following individuals:

  • R. Brad Martin will serve as chairman of the FedEx Freight board as previously announced. He has served as executive chairman of the board of FedEx Corp. since September 2025, and is also chairman of RBM Venture Company, a private investment company. Mr. Martin previously served as chairman and chief executive officer of Saks Incorporated and has held leadership and board roles at multiple public companies, including Chesapeake Energy Corporation.
  • John A. Smith will serve as a member of the FedEx Freight board and president and chief executive officer of FedEx Freight upon completion of the separation. He is currently chief operating officer of U.S. and Canada for FedEx Corp. and a member of the FedEx Corp. executive committee. Mr. Smith previously served as president and chief executive officer of FedEx Ground and FedEx Freight and brings more than 30 years of transportation industry experience.
  • Jeffrey A. Davis served as the chief financial officer of Dollar Tree, Inc. from October 2022 to March 2025; as the chief financial officer of Qurate Retail Group from October 2018 to September 2022; as the chief financial officer of J. C. Penney Company Inc. from July 2017 to September 2018; as the chief financial officer of Darden Restaurants, Inc. from July 2015 to March 2016; and as the chief financial officer of the Walmart U.S. segment of Walmart Inc. from January 2014 to May 2015. Mr. Davis has served as a director of Labcorp Holdings, Inc. since December 2019 where he serves as the chairman of the Audit Committee and as a member of the Quality and Compliance Committee. Mr. Davis is well-qualified to serve as a member of the FedEx Freight board because of his extensive financial leadership experience across multiple industries.
  • Donald E. Frieson served as executive vice president, supply chain of Lowe’s Companies, Inc. from August 2018 to March 2024. He previously spent 19 years within the Walmart organization, where he served as executive vice president, operations at Sam’s Club from 2014 to 2017 and senior vice president, replenishment, planning, and real estate from 2012 to 2014. Mr. Frieson has served as a director of Casey’s General Stores, Inc. since March 2018 where he serves as a member of the Compensation and Human Capital Committee. He served as a member of the Advisory Committee for Supply Chain Competitiveness for the U.S. Department of Commerce from February 2022 to February 2024. Mr. Frieson is well-qualified to serve as a member of the FedEx Freight board because of his significant leadership experience in supply chain management.
  • Stephen E. Gorman served as chief executive officer of Air Methods Corporation, a leading domestic provider in the air medical market, from August 2018 to January 2020. He previously served as the president and chief executive officer of Borden Dairy Company from 2014 to July 2017; as the executive vice president and chief operating officer of Delta Air Lines, Inc. from 2008 to 2014; as the executive vice president – operations of Delta Air Lines from 2007 to 2008; and as the president and chief executive officer of Greyhound Lines, Inc. from 2003 to 2007. Mr. Gorman has served as a director of Peabody Energy Corporation since April 2017 where he serves as chairman of the Nominating & Corporate Governance Committee and as a member of the Compensation Committee and the Executive Committee, and as a director of FedEx Corp. since September 2022 where he serves as a member of the Compensation and Human Resources Committee and the Governance, Safety, and Public Policy Committee. Mr. Gorman will resign from the FedEx Corp. board effective upon his joining the FedEx Freight board upon the separation. He served as a director of ArcBest Corporation from July 2015 to August 2022 and as the company’s lead independent director from January 1, 2022 until his resignation to join the FedEx Corp. board. Mr. Gorman is well-qualified to serve as a member of the FedEx Freight board because of his significant transportation and logistics leadership experience.
  • Robert A. King served as corporate vice president, internal audit at FedEx Corp. from March 2011 to January 2025. He spent over four decades of his career in the FedEx Internal Audit department, holding positions with increasing responsibility. Mr. King is well-qualified to serve as a member of the FedEx Freight board because of his extensive financial and risk management experience during his tenure at FedEx.
  • Cindy J. Miller served as the president and chief executive officer of Stericycle, Inc., a medical waste transportation company, from May 2019 to November 2024 when the company was acquired by Waste Management, Inc. and as a director of the company from February 2019 to November 2024. She served as president and chief operating officer of Stericycle, Inc. from October 2018 to May 2019. Prior to joining Stericycle, Inc., Ms. Miller spent nearly 30 years at United Parcel Service, Inc. (“UPS”) where she served as president, global freight forwarding from April 2016 to September 2018 and as president of the European region from March 2013 to March 2016. Ms. Miller has served as a director of W.W. Grainger, Inc. since April 2024 where she serves as a member of the Board Affairs & Nominating Committee and Compensation Committee. She also serves on the Board of Trustees of the Allspring Fund complex, which includes four closed-end funds. She served as a director of UGI Corporation from 2020 to 2024. Ms. Miller is well-qualified to serve as a member of the FedEx Freight board because of her significant leadership experience in the transportation and logistics industry.
  • Amy J. Salcido served as president, U.S. of Kyndryl Holdings, Inc., a Fortune 500 provider of enterprise technology services spun off from International Business Machines Corporation (“IBM”) in 2021, from 2022 to 2025. She previously served as chief customer engagement & transformation officer from 2021 to 2022. Before joining Kyndryl, Ms. Salcido held senior leadership roles at IBM, including as general manager, services: retail, consumer products, travel & transportation — North America from 2020 to 2021, and as global vice president, new client acquisition from 2018 to 2020. She joined IBM in 1996 and held positions with increasing responsibility during her tenure with the company. Ms. Salcido was named No. 15 in Technology Magazine’s “Top 100 Women in Technology” in 2025. Ms. Salcido is well-qualified to serve as a member of the FedEx Freight board because of her significant technology experience and leadership experience with large-scale public company separation.
  • John P. Sauerland has served as vice president and chief financial officer of The Progressive Corporation since April 2015 and as personal lines group president of The Progressive Corporation from 2007 to 2015. He joined The Progressive Corporation in 1991 as a product manager and has served in many key leadership positions during his tenure with the company. Mr. Sauerland served as a director of Beazley plc from 2016 to 2021. Mr. Sauerland is well-qualified to serve as a member of the FedEx Freight board because of his extensive leadership experience in finance and risk management.
  • Samantha M. Smith currently serves as a staff director of global public policy at FedEx Corp., a position she has held since November 2020. It is expected that she will continue her employment at FedEx Corp. following the spin-off. Ms. Smith joined the FedEx Corp. Government and Regulatory Affairs team in 2016. Prior to FedEx Corp. she served in various roles in communications and public affairs. Ms. Smith is well-qualified to serve as a member of the FedEx Freight board because of her extensive experience in government affairs, public policy, and communications, including at FedEx Corp.

Goldman Sachs & Co. LLC is serving as the financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel.

About FedEx Corp.

FedEx Corp. (NYSE: FDX) provides customers and businesses worldwide with a broad portfolio of transportation, e-commerce, and business services. With annual revenue of $90 billion, the company offers integrated business solutions utilizing its flexible, efficient, and intelligent global network. Consistently ranked among the world’s most admired and trusted employers, FedEx inspires its more than 500,000 employees to remain focused on safety, the highest ethical and professional standards, and the needs of their customers and communities. FedEx is committed to connecting people and possibilities around the world responsibly and resourcefully, with a goal to achieve carbon-neutral operations by 2040. To learn more, please visit fedex.com/about.

About FedEx Freight

FedEx Freight, Inc. is North America’s largest less-than-truckload (LTL) carrier, delivering industry-leading transit times, service levels, and reliability. FedEx Freight’s service offerings – including Priority, Economy, and Direct – allow customers to balance speed and cost to meet their unique needs. FedEx Custom Critical, a subsidiary of FedEx Freight, provides expedited, time- and temperature-specific freight solutions, including Surface Expedite and White Glove Services, available 24/7/365. With nearly 30,000 vehicles and 39,000 dedicated team members to support its unmatched network of approximately 355 service centers, we ensure freight arrives safely, securely, and on time across all 50 U.S. states, Canada, Mexico, Puerto Rico, and the U.S. Virgin Islands. After the spin-off, FedEx Freight will operate as an independent company, leveraging operational efficiency, data-driven technology, and a focused sales organization to provide outstanding service. For more information, visit fedex.com/about.

Cautionary Statement Regarding Forward-Looking Information

Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act (the “PSLRA”), such as statements regarding the planned separation of FedEx Freight into a new publicly traded company (the “FedEx Freight Spin-Off”), business strategies, management’s views with respect to future events and financial performance, and the assumptions underlying such statements. Forward-looking statements include those preceded by, followed by or that include the words “will,” “may,” “could,” “would,” “should,” “believes,” “expects,” “forecasts,” “anticipates,” “plans,” “estimates,” “targets,” “projects,” “intends” or similar expressions. Such forward-looking statements, which are intended to enjoy the protection of the safe harbor for forward-looking statements provided by the PSLRA as well as other legal protections, are subject to risks, uncertainties and other factors which could cause actual results to differ materially from historical experience or from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, FedEx’s ability to satisfy required closing conditions and successfully implement the FedEx Freight Spin-Off and achieve the anticipated benefits of such transaction and other factors which can be found in FedEx’s and its subsidiaries’ press releases and FedEx’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended May 31, 2025 and subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it is made. FedEx does not undertake or assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Media contact:

Caitlin Maier

901-434-8100

[email protected]

Investor Relations Contact:

Jeni Hollander

901-818-7200

[email protected]

KEYWORDS: Tennessee United States North America

INDUSTRY KEYWORDS: Trucking Rail Automotive Air Logistics/Supply Chain Management Transport Fleet Management

MEDIA:

Logo
Logo
Posted on

EHang Appoints Mr. Shuai Feng as Chief Technology Officer to Deepen Technological Innovation and Industrial Synergy, Empowering Commercialization

GUANGZHOU, China, Jan. 16, 2026 (GLOBE NEWSWIRE) — EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), a global leader in advanced air mobility (“AAM”) technology, today officially announced that the Board of Directors of the Company (the “Board”) has approved and appointed Mr. Shuai Feng as the Chief Technology Officer (“CTO”), effective on January 14, 2026. This appointment represents a key milestone in the Company’s technology strategy. Building on the solid foundation established through years of direct leadership over technology development by the Company’s Founder, Chairman, and Chief Executive Officer Mr. Huazhi Hu, EHang is advancing its technology management framework toward systematic innovation and industrial implementation.

(Mr. Shuai Feng, CTO of EHang)

Since the Company’s inception, Mr. Hu has personally led EHang’s core technology development with a clear technical vision and firm strategic direction, comprehensively overseeing the integrated initiatives across technology research and development (“R&D”), production and manufacturing, quality systems, and supply chain integration. Focusing on the Company’s core AAM strategy, he has guided the team through multiple breakthroughs in key unmanned aerial vehicle (“UAV”) and electric vertical take-off and landing (“eVTOL”) aircraft technologies and certifications, laying a strong technological foundation and establishing EHang’s industry-leading position. Throughout this process, Mr. Hu has placed strong emphasis on cultivating and developing core technical talent, with Mr. Feng being a next-generation technology leader the Company has invested in over many years.

Mr. Feng joined EHang in July 2014 as a core member of the founding team. Under Mr. Hu’s strategic guidance and technical philosophy, he has played a critical role in and led the development of, multiple pilotless human-carrying eVTOLs products, including the EH184, the EH216-S, and the VT35, as well as the GD series aerial formation UAVs. These innovations pioneered commercialization in global pilotless AAM and aerial media performance applications.

In addition, as the Company has entered a new phase of commercialization, and in alignment with Mr. Hu’s full-industry-chain integration strategy, Mr. Feng has in recent years taken on key responsibilities in building EHang’s procurement and supply chain management systems. By strengthening upstream and downstream coordination, enhancing productization efficiency, and advancing deep industry-chain integration and regional ecosystem development, he has significantly enhanced EHang’s capabilities for key components R&D and scaled manufacturing. Currently, Mr. Feng also serves as the Company’s Compliance Officer, continuously upholding EHang’s development principles of “safety, compliance, innovation, and sustainability” through his cross-functional leadership roles.

Mr. Feng graduated from Tsinghua University in Automation major, where he specialized UAV technology and was awarded the Grand Prize in the University’s prestigious 29th “Challenge Cup” competition, among other honors. He currently serves as Deputy Director of the Tsinghua-EHang Joint Research Institute for Low-Altitude Aviation Technology, Deputy Secretary-General of the Aerospace, Aviation, and Smart Manufacturing Committee of the Tsinghua University Guangzhou Alumni Association, and Secretary-General of the Tsinghua University Future Robotics Interest Group. His academic background and industry influence will further support the execution and deepening of the Company’s technology strategy.

Mr. Huazhi Hu stated, “Since the early days of the Company, Mr. Feng has worked closely under my direct leadership and has been deeply involved in the buildup of EHang’s technology system. He has consistently upheld our core technology philosophy and has made significant contributions by precisely executing our strategic direction across critical stages across R&D, manufacturing, and certification. As EHang enters a new phase of commercial operations and global expansion, appointing Mr. Feng’s as CTO is a further step to ensure continuity of our core technology strategy and talent development philosophy. Under my overall direction and guidance, he will further integrate technology, production, and supply chain resources, ensure strategic alignment and disciplined execution, and supporting EHang’s long-term vision of building safe, scalable, and sustainable AAM solutions.”

Mr. Shuai Feng commented, “I would like to sincerely thank the Board and the management team for their trust and especially express my deep gratitude to Mr. Hu for his personal mentorship, guidance, and confidence over the past decade. I have witnessed EHang’s journey from early innovation to commercial deployment under Mr. Hu’s technology-driven strategy, and have gained a deep understanding of the Company’s core technical philosophy and long-term vision. Looking ahead, I will continue to take Mr. Hu’s technology principles as my guide, strictly adhere to the Company’s established technology strategy, and work closely with the team to integrate technology development with manufacturing and quality control. I am committed to improving execution and production efficiency, further supporting the Company’s continued technology innovation and industrial implementation with a strong sense of responsibility.”

About EHang

EHang (Nasdaq: EH) is the world’s leading advanced air mobility (“AAM”) technology platform company, committed to making safe, autonomous, and eco-friendly air mobility accessible to everyone. The company develops and manufactures a diversified portfolio of pilotless electric vertical take-off and landing (“eVTOL”) aircraft for a wide range of use cases, including aerial tourism, intra-city transport, intercity travel, logistics and emergency firefighting. Its flagship model, EH216-S, has obtained the world’s first type certificate, production certificate and standard airworthiness certificate for pilotless eVTOL issued by the Civil Aviation Administration of China, and is now commercially operated under the country’s first Air Operator Certificates for human-carrying eVTOL services. Complementing this, EHang’s VT35 expands its reach into long-range and intercity scenarios, supporting the development of a multi-tiered low-altitude mobility network. By integrating advanced autonomous technologies with scalable operational infrastructure, EHang is redefining how people and goods move—across cities, regions, and natural barriers—shaping the future of air mobility. For more information, please visit www.ehang.com.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements. Statements that are not historical facts, including statements about management’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to those relating to certifications, our expectations regarding demand for, and market acceptance of, our products and solutions and the commercialization of UAM services, our relationships with strategic partners, and current litigation and potential litigation involving us. Management has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While they believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond management’s control. These statements involve risks and uncertainties that may cause EHang’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

Media Contact: [email protected]
Investor Contact: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d29af122-aa25-44a7-9428-6b23f6e94293



Posted on

SUNSTONE HOTEL INVESTORS SCHEDULES FOURTH QUARTER AND FULL YEAR 2025 EARNINGS RELEASE AND CONFERENCE CALL

PR Newswire

ALISO VIEJO, Calif., Jan. 16, 2026 /PRNewswire/ — Sunstone Hotel Investors, Inc. (the “Company” or “Sunstone”) (NYSE: SHO) announced that it will report financial results for the fourth quarter and full year 2025 on Friday, February 27, 2026, before the market opens. Management will hold its quarterly conference call the same day, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time).

A live webcast of the call will be available through the Investor Relations section of the Company’s website at www.sunstonehotels.com. A transcript of the call will also be archived on the website. Alternatively, interested parties may dial 1-800-715-9871 and reference Conference ID 1026321 to listen to the live call.


About Sunstone Hotel Investors:

Sunstone Hotel Investors, Inc. is a lodging real estate investment trust (“REIT”). Sunstone’s strategy is to create long-term stakeholder value through the acquisition, active ownership, and disposition of well-located hotel and resort real estate. For further information, please visit Sunstone’s website at www.sunstonehotels.com.


For Additional Information:

Aaron Reyes
Chief Financial Officer
Sunstone Hotel Investors, Inc.
(949) 382-3018

Cision View original content:https://www.prnewswire.com/news-releases/sunstone-hotel-investors-schedules-fourth-quarter-and-full-year-2025-earnings-release-and-conference-call-302662980.html

SOURCE Sunstone Hotel Investors, Inc.

Posted on

GIBO.ai Transforms Aerial Mobility Data into AI-Driven Intelligence Services for Industry, Energy, and Sustainability Markets

PR Newswire

HONG KONG, Jan. 16, 2026 /PRNewswire/ — GIBO Holdings Ltd. (NASDAQ: GIBO), Asia’s leading innovation-driven AI ecosystem, today announced the next phase of its AI aviation roadmap, extending the GIBO.ai Calculation Engine beyond flight operations to deliver AI-powered aerial intelligence and data analytics services for commercial, industrial, and sustainability-focused markets.

Building on its expansion into scalable AI-powered eVTOL platforms, GIBO is now positioning aerial systems as data-generating intelligence assets, capable of producing high-value insights that support infrastructure planning, environmental assessment, energy optimization, and ESG-driven decision-making.

From Flight Platforms to Intelligence Services

Modern eVTOL aircraft generate vast volumes of real-time data, including environmental sensing, terrain imaging, flight dynamics, and operational telemetry. Through the GIBO.ai Calculation Engine, this raw data is transformed into structured, actionable intelligence that can be applied across multiple industries.

Rather than treating aerial vehicles solely as mobility solutions, GIBO.ai enables them to function as intelligent data nodes, continuously capturing and analyzing information from the physical world. This shift allows aerial operations to deliver ongoing analytical value long after each mission is completed.

AI Calculation Converts Aerial Data into Actionable Insights

The GIBO.ai Calculation Engine applies advanced AI models to interpret aerial data streams, enabling precise analysis of terrain conditions, infrastructure integrity, environmental patterns, and operational risk. By combining real-time computation with post-mission analytics, the system produces insights that are both immediate and longitudinal.

These AI-calculated outputs can support use cases such as infrastructure inspection, energy asset monitoring, geological assessment, environmental impact analysis, and site-planning optimization. As a result, enterprises gain deeper visibility into physical environments that are traditionally difficult, costly, or time-consuming to assess.

Supporting Sustainability, ESG, and Green Economy Applications

A core focus of this initiative is the application of AI-derived aerial intelligence to sustainability and environmental performance measurement. GIBO.ai enables organizations to quantify environmental conditions, monitor change over time, and validate operational impact with data-driven confidence.

By converting aerial observations into verifiable datasets, the platform supports ESG reporting, sustainability benchmarking, and compliance with emerging environmental standards. This positions GIBO.ai as a foundational intelligence layer for companies seeking to integrate environmental accountability into their operations.

“The true value of AI-powered aviation lies in the intelligence it produces.”

“Aerial platforms are becoming one of the most efficient ways to observe and understand the physical world,” said Zelt Kueh, CEO of GIBO Holdings Ltd.
“With the GIBO.ai Calculation Engine, flight data evolves into intelligence services that industries can rely on for planning, optimization, and sustainability. This is where AI moves beyond mobility and becomes a decision-making engine for the green economy.”

A Scalable Intelligence Model for Multiple Industries

The aerial intelligence services enabled by GIBO.ai are designed to scale across sectors, supporting energy infrastructure, environmental services, logistics planning, smart-city development, and future mobility ecosystems. As data accumulates over time, the AI models continue to learn, improving accuracy, predictive capability, and long-term value.

This data-centric approach complements GIBO’s broader vision of integrating AI across air and ground mobility systems, enabling a unified intelligence framework that connects transportation, infrastructure, and sustainability analytics.

About GIBO Holdings Limited

GIBO Holdings Ltd. is a unique and integrated AIGC animation streaming platform with extensive functionalities provided to both viewers and creators that serves a broad community of young people across Asia to create, publish, share and enjoy AI-generated animation video content. With over 83 million registered users and advanced AI-powered tools, GIBO seeks to redefine the landscape of digital content creation.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements also include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, the Company’s ability to scale and grow its business, the Company’s advantages and expected growth, the Company’s ability to source and retain talent, and the Company’s cash position, as applicable. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These statements involve risks, uncertainties and other factors that may cause the Company’s actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained in this press release, the Company cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. The forward-looking statements in this press release represent the views of the Company as of the date of this press release. Subsequent events and developments may cause those views to change. Except as may be required by law, the Company does not undertake any duty to update these forward-looking statements.

Contact Information

Investor Relations:
Bill Zima
ICR, Inc.
[email protected] 

Media Relations:
Edmond Lococo
ICR, Inc.
[email protected]

For more information and the latest updates, please visit:


https://www.globalibo.com/gibo-click/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/giboai-transforms-aerial-mobility-data-into-ai-driven-intelligence-services-for-industry-energy-and-sustainability-markets-302663303.html

SOURCE GIBO Holdings Ltd.

Posted on

Clorox Expands Partnership with Realize the Dream to Mobilize Employee Volunteer Service Globally

PR Newswire

Key News

  • The Clorox Company commits 300,000 employee volunteer hours to support thriving communities and advance Realize the Dream’s goal of 100 million service hours by 2029.
  • Building on its Oakland, California roots, Clorox expands its partnership with Realize the Dream, mobilizing teammates to support schools, families, and community well-being through hands-on service and educational resources.
  • Clorox’s multi-year commitment honors Dr. Martin Luther King Jr.’s legacy, engaging employees in service that promotes inclusion, health, and opportunity for all.

OAKLAND, Calif., Jan. 16, 2026 /PRNewswire/ — The Clorox Company (NYSE: CLX) today announced its expanded partnership with Realize the Dream, a national service initiative honoring Dr. Martin Luther King Jr.’s message of connecting people through service. The new Clorox initiative, Every Hour Counts, is a multi-year commitment to mobilize thousands of employees globally toward Realize the Dream’s ambitious goal of 100 million volunteer hours by 2029, coinciding with Dr. King’s 100th birthday.

“This effort reflects Clorox’s long-standing history of giving back and our deep commitment to supporting local communities,” said Chief Diversity and Social Impact Officer Shanique Bonelli-Moore. “By pledging 300,000 volunteer hours and partnering with Realize the Dream, we are honoring Dr. King’s legacy while mobilizing our teammates to live our purpose every day. When the communities we serve are well and thriving, Clorox is stronger too.”

This commitment builds on the existing partnership between Realize the Dream and the Clorox brand, launched in 2025, which includes a donation of two million Clorox Disinfecting Wipes to schools and communities across the U.S. as well as the development and deployment of a free K–6 curriculum designed to help teachers and parents foster practical life skills and uplift communities through the feel-good power of clean. The expanded partnership extends this impact, engaging Clorox teammates across the globe in meaningful service that brings the company’s purpose to life in communities where they live and work.

“Martin Luther King Jr. taught us that service is not charity. It is the work of justice and the pathway to the Beloved Community,” said Martin Luther King III and Arndrea Waters King, Co-Founders of Realize the Dream. “The Clorox Company’s pledge of 300,000 hours is a powerful step toward our goal of 100 million hours of service by 2029. That is how we honor the legacy of Martin Luther King Jr., by rolling up our sleeves and working side by side to build the future our children deserve.”

Clorox and its portfolio of brands have a long-standing legacy of giving back through nonprofit partnerships and community involvement where its employees live and work. On a national and international level, the company has partnerships with the American Red Cross and other organizations with an emphasis on community wellness, disease prevention and disaster relief.

About The Clorox Company

The Clorox Company (NYSE: CLX) champions people to be well and thrive every single day. Headquartered in Oakland, California since 1913, Clorox integrates sustainability into how it does business. Driven by consumer-centric innovation, the company is committed to delivering clearly superior experiences through its trusted brands including Brita®, Burt’s Bees®, Clorox®, Fresh Step®, Glad®, Hidden Valley®, Kingsford®, Liquid-Plumr® and Pine-Sol® as well as international brands such as Chux®, Clorinda® and Poett®. Visit thecloroxcompany.com to learn more.

About Realize the Dream

With the leadership of Martin Luther King III, Arndrea Waters King, and Yolanda Renee King, Realize the Dream seeks to inspire generational change and mobilize 100 million hours of service by 2029, marking the 100th anniversary of Dr. King’s birth. By uniting Americans through service, the initiative fosters connection, builds empathy, and advances collective action nationwide. Learn more and get involved at realizethedream.org.

CLX-C

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/clorox-expands-partnership-with-realize-the-dream-to-mobilize-employee-volunteer-service-globally-302662986.html

SOURCE The Clorox Company

Posted on

Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape

PR Newswire


Issued on behalf of GT Biopharma, Inc.

VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ — Equity InsiderNews Commentary – The precision medicine sector is undergoing a structural realignment toward platform-based biologics, as the market prepares to surge from $138 billion this year to over $537 billion by 2035[1]. This shift marks the end of “one-size-fits-all” treatments, as investors rotate capital into modular systems designed to hunt multiple cancer targets at once. This secular transition is creating massive opportunities for specialized platforms that can scale across high-prevalence killers like lung, breast, and pancreatic cancers, led by GT Biopharma, Inc. (NASDAQ: GTBP), ImmunityBio (NASDAQ: IBRX), Erasca, Inc. (NASDAQ: ERAS), NovaBridge Biosciences (NASDQ: NBP), and Coherus Oncology (NASDAQ: CHRS).

Biological cancer therapies anchored by NK-cell platforms and CAR-based modalities[2] are projected to reach $225 billion by 2030, finally cracking the code on the “armored” microenvironments of solid tumors. Institutions are now positioning for an immuno-oncology expansion to $185.69 billion by 2035[3] as the industry enters the “Immunotherapy 2.0” era. With next-generation bispecific antibody frameworks scaling from $11.29 billion toward $52.08 billion by 2035[4], the 2026 clinical cycle is proving that the real value lies in the “code” of the platform itself.

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical-stage immuno-oncology company, recently announced that it submitted an investigational new drug application to the FDA in December 2025 for GTB-5550, a B7-H3-targeted natural killer cell engager designed to treat solid tumor cancers. The company develops next-generation immunotherapy treatments through its proprietary TriKE platform, which harnesses natural killer cells to attack cancer.

GTB-5550 represents GT Biopharma’s third NK cell engager advancing toward clinical development, targeting B7-H3, a protein prevalent across breast, lung, ovarian, pancreatic, prostate, bladder, and head and neck cancers.

The therapy addresses a portion of the estimated $362 billion global solid tumor market according to Data Bridge Market Research. Designed as a subcutaneous injection administered in the abdominal area for five consecutive days during weeks one and two followed by two weeks off treatment, GTB-5550 offers potential for more patient-friendly dosing compared to continuous infusion schedules. The planned Phase 1 basket trial will evaluate GTB-5550 across seven distinct metastatic disease cohorts.

“The IND for GTB-5550 represents another NK cell engager we plan to move into clinical development and a tremendous accomplishment for the company,” said Michael Breen, Executive Chairman and CEO of GT Biopharma. “As we continue actively enrolling the Phase 1 trial with GTB-3650 in myeloid blood cancer, we expect the next data readout in 1H 2026 could provide potential evidence of clinical activity. Initiation of a Phase 1 basket trial with GTB-5550 for multiple solid tumors is planned for 2026. We look forward to applying the clinical learnings from the GTB-3650 study to help inform the GTB-5550 program, which targets a patient population with B7-H3 expressing solid tumors that is orders of magnitude larger than the myeloid blood cancer patient population.”

Meanwhile, GT Biopharma continues advancing its Phase 1 clinical trial of GTB-3650 to Cohort 4, where patients now receive 10μg/kg/day dosing. The trial evaluates GTB-3650 in patients with relapsed or refractory blood cancers expressing CD33, particularly acute myeloid leukemia and high-risk myelodysplastic syndrome. The six patients enrolled through Cohorts 1, 2, and 3 completed treatment successfully, establishing the therapy’s safety profile with zero dose-limiting toxicities.

Both therapeutic candidates leverage GT Biopharma’s proprietary TriKE platform utilizing specialized antibody fragments initially discovered in camels and llamas, providing advantages through compact size and enhanced stability.

GT Biopharma’s dual-program advancement positions the company to address both blood cancers and solid tumors, potentially expanding its addressable patient population significantly as clinical data emerges throughout 2026.


CONTINUED… Read this and more news for GT Biopharma, Inc. at:
 
https://equity-insider.com/2025/10/03/the-small-biotech-thats-cracking-the-code-big-pharma-paid-billions-for/

ImmunityBio (NASDAQ: IBRX)
reports continued execution and sales momentum with preliminary net product revenue of approximately $113 million for fiscal year 2025, representing a 700% year-over-year increase for ANKTIVA. The commercial-stage biotechnology company delivered fourth quarter preliminary revenue of approximately $38.3 million, marking a 20% sequential increase and a 431% year-over-year improvement, while demonstrating 750% unit sales volume growth during 2025.

“We delivered strong quarter-over-quarter revenue growth, reflecting accelerating adoption of ANKTIVA and the continued execution of our commercial strategy,” said Richard Adcock, President and CEO of ImmunityBio. “This momentum is further reinforced by the approval of ANKTIVA plus BCG in Saudi Arabia, building on existing approvals in the U.S. and U.K, as well as conditional approval in the EU.”

ImmunityBio continues advancing its first-line NMIBC program, with enrollment in the ongoing Phase 2b QUILT-2.005 trial progressing ahead of internal expectations and full enrollment anticipated in the first half of 2026. The company ended the quarter with an estimated $242.8 million in cash, cash equivalents and marketable securities as of December 31, 2025.

Erasca, Inc. (NASDAQ: ERAS) announces promising data for ERAS-0015 with confirmed partial responses in multiple tumor types during dose escalation, demonstrating clinical activity at doses as low as 8 mg once daily. The clinical-stage precision oncology company reported encouraging early clinical activity coupled with favorable safety, tolerability, and well-behaved pharmacokinetics for its pan-RAS molecular glue, with the AURORAS-1 Phase 1 trial enrolling ahead of plan.

“During dose escalation, ERAS-0015 has already demonstrated promising early clinical activity with multiple ongoing confirmed and unconfirmed responses achieved, along with encouraging safety and tolerability data and well-behaved PK,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “We believe that observing first clinical responses in multiple patients at just 1/10th of the dose at which first clinical responses were observed with RMC-6236 is thesis-reinforcing in terms of ERAS-0015’s potential differentiation.”

Initial Phase 1 monotherapy data for ERAS-0015 is planned for the first half of 2026, with initiation of monotherapy expansion cohorts and combination dose escalation cohorts planned for the second half of 2026. Erasca expects to report monotherapy expansion data and combination dose escalation data during 2027.

NovaBridge Biosciences (NASDAQ: NBP) presents positive data from the Phase 1b combination study of givastomig with 77% ORR at 8 mg/kg and 73% ORR at 12 mg/kg in first-line HER2-negative metastatic gastric cancer patients. The global biotechnology platform company reported median progression-free survival of 16.9 months at 8 mg/kg, with the CLDN18.2 x 4-1BB bispecific antibody demonstrating robust efficacy when combined with nivolumab and mFOLFOX6 chemotherapy across wide ranges of PD-L1 and CLDN18.2 expression levels.

“The dose expansion data reinforce the strong signals we observed in dose escalation. The efficacy is clear at 8 mg/kg, with robust ORRs, including in subgroups defined by low PD-L1 and/or CLDN18.2 expression,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “We remain enthusiastic about the 12 mg/kg dose because exposure analysis shows higher exposure is consistently associated with a higher probability of response, without a higher probability of toxicity.”

NovaBridge is on track to initiate enrollment in a global, randomized Phase 2 study evaluating both doses against standard of care in Q1 2026. The combination was well tolerated with safety comparable to current standard of care treatment, with detailed Phase 1b dose expansion data expected to be presented at a medical conference later in 2026.

Coherus Oncology (NASDAQ: CHRS) announces publication in Molecular Cancer Therapeutics highlighting the strong pharmacology of investigational CCR8 antibody tagmokitug, formerly CHS-114. The commercial-stage innovative oncology company reported preclinical and clinical biomarker research demonstrating picomolar binding affinity, high selectivity for CCR8 with no off-target binding, and significant effector-mediated killing of CCR8+ cells, with the antibody selectively eliminating CCR8+ T regulatory cells while sparing other T cells.

“This publication presents the robust pharmacology of tagmokitug in preclinical and clinical studies, and with a selectivity profile and potent binding and killing of CCR8+ T regulatory cells and not other immune cells,” said Theresa LaVallee, PhD, Chief Scientific and Development Officer at Coherus. “The data show a high abundance of CCR8 target expression in a broad range of solid tumors suggesting the promise of the tagmokitug program.”

Tagmokitug is currently being evaluated in Phase 1b/2a clinical trials in patients with solid tumors in combination with toripalimab and chemotherapy. First-in-human clinical study data established proof of mechanism with translational data showing tagmokitug administration leads to selective reductions in CCR8+ Tregs and not other T cell subsets in cancer patients.


Article Sources: 


https://equity-insider.com/2025/10/03/the-small-biotech-thats-cracking-the-code-big-pharma-paid-billions-for/

CONTACT:

Equity Insider


[email protected]


(604) 265-2873


DISCLAIMER:
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed by Equity Insider on behalf of Market IQ Media Group Inc. (“MIQ”). MIQ has been paid a fee for GT Biopharma, Inc. advertising and digital media from Creative Digital Media Group (“CDMG”). There may be 3rd parties who may have shares of GT Biopharma, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY does not own any shares of GT Biopharma, Inc. but reserve the right to buy and sell, and will buy and sell shares of GT Biopharma, Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved on behalf of GT Biopharma, Inc. by CDMG; this is a paid advertisement, we currently own shares of GT Biopharma, Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES CITED:
1.   https://www.precedenceresearch.com/precision-medicine-market
2.   https://www.globenewswire.com/news-release/2026/01/14/3219034/0/en/BCC-Research-Forecasts-7-5-CAGR-for-Global-Biological-Cancer-Therapies-Market.html
3.   https://www.globenewswire.com/news-release/2026/01/14/3218904/0/en/The-185B-Cancer-Surge-Why-the-FDA-s-Fast-Track-Pivot-is-Scaling-a-New-Immunotherapy-Era.html
4.   https://www.precedenceresearch.com/next-generation-bispecific-antibody-market

Logo – https://mma.prnewswire.com/media/2840019/Equity_Insider_Logo.jpg

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/functional-force-precision-platforms-disrupt-the-2026-tumor-landscape-302663334.html

Posted on

Wingstop Inc. to Announce Fiscal Fourth Quarter 2025 Financial Results on February 18, 2026

PR Newswire

DALLAS, Jan. 16, 2026 /PRNewswire/ — Wingstop Inc. (NASDAQ: WING) today announced that it will host a conference call and webcast to discuss its fiscal fourth quarter and full year 2025 financial results on Wednesday, February 18, 2026 at 10:00 a.m. ET.

A press release with fiscal fourth quarter and full year 2025 financial results will be issued before the market opens that morning.

The conference call can be joined telephonically by dialing 1-877-259-5243 or 1-412-317-5176 (international) and asking for the Wingstop conference call. A replay will be available two hours after the call and can be accessed by dialing 1-855-669-9658 or 1-412-317-0088 (international), then entering the replay code 4161830. The replay will be available through Wednesday, February 25th, 2026.

The conference call will also be webcast live and later archived on the investor relations section of Wingstop’s corporate website at ir.wingstop.com under the ‘News & Events’ section. The webcast can also be accessed directly at https://event.choruscall.com/mediaframe/webcast.html?webcastid=U7IjpSr1.

About Wingstop

Founded in 1994 and headquartered in Dallas, TX, Wingstop Inc. (NASDAQ: WING) operates and franchises more than 2,800 restaurants worldwide – with 98% of the total restaurant count owned by brand partners. Dedicated to Serving the World Flavor, the Flavor Experts offer cooked-to-order and hand sauced-and-tossed classic and boneless wings, tenders and chicken sandwiches, in fans’ choice of 12 bold, distinctive flavors, with signature sides and iconic housemade ranch and bleu cheese dips. With approximately $5 billion in system-wide sales in fiscal 2024, 21 consecutive years of same-store sales growth and a vision to become a Top 10 Global Restaurant Brand, Wingstop was recently named the Official Chicken Partner of the NBA. Learn more at wingstop.com or follow @Wingstop on X, Instagram, Facebook and TikTok.

Media Contact

Kyra Harbert
[email protected]

Investor Contact

Sarah Niehaus
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/wingstop-inc-to-announce-fiscal-fourth-quarter-2025-financial-results-on-february-18-2026-302663164.html

SOURCE Wingstop Restaurants Inc.

Posted on

ITHAX Acquisition Corp III Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing January 20, 2026

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) — ITHAX Acquisition Corp III (NASDAQ: ITHAU) (the “Company”) announced that, commencing January 20, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Global Market under the symbols “ITHA” and “ITHAW,” respectively. Those units not separated will continue to trade on the Nasdaq Global Market under the symbol “ITHAU.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A ordinary shares and warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.


About ITHAX Acquisition Corp III

ITHAX Acquisition Corp III (www.ithaxacquisition.com) is a newly organized blank check company sponsored by Orestes Fintiklis, founder of Ithaca Capital Partners, a private equity manager. Orestes Fintiklis was also sponsor and Chief Executive Officer of ITHAX Acquisition Corp.


Media Contact

Orestes Fintiklis
[email protected]



Posted on

Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds

LITTLETON, Colo., Jan. 16, 2026 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced that it has entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023, and February 20, 2024, at exercise prices ranging from $3.83 to $5.05 per share, at a reduced exercise price of $2.34 per share. The shares of common stock issuable upon exercise of the warrants are registered for resale pursuant to effective registration statement on Form S-3 (Registration No. 333- 278564). The gross proceeds to the company from the exercise of the warrants are expected to be approximately $4.64 million, prior to deducting placement agent fees and offering expenses.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

As consideration for the exercise of such existing warrants for cash, the Company will issue in a private placement new unregistered warrants to purchase up to an aggregate of 3,964,712 shares of common stock at an exercise price of $2.09 per share, which warrants will be exercisable immediately upon issuance and, with respect to warrants to purchase up to 1,982,356 shares of common stock, will expire five years following the date of issuance, and with respect to warrants to purchase up to 1,982,356 shares of common stock, will expire twenty-four months following the date of issuance.

The offering is expected to close on or about January 20, 2026, subject to satisfaction of customary closing conditions. Vivos intends to use the net proceeds from the offering for working capital and general corporate purposes.

The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the 1933 Act) and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements. The company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children.

OSA affects over 1 billion people worldwide, yet 90% remain undiagnosed and unaware of their condition. This chronic disorder is not just a sleep issue—it is closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes of OSA.

Founded in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.

Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.

For more information, visit www.vivos.com

Cautionary Note Regarding Forward-Looking Statements

This press release, including statements of the Company’s management and other parties made in connection therewith, contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “would”, “should”, “expects”, “projects,” “potential,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal”. “aim” and variations of such words and similar expressions are intended to identify forward-looking statements. In this press release, forward-looking statements include, without limitation, those relating to the completion of the offering; the satisfaction of customary closing conditions, the intended use of proceeds from the offering and the anticipated closing of the offering. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to continue to integrate business from the acquisition and alliance model into its own or otherwise implement sales, marketing and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (iv) the risk that Vivos may be unable to secure additional financing to continue operations, acquire additional sleep centers practices on reasonable terms, or maintain its Nasdaq listing when needed, if at all, (v) market and other conditions that could impact Vivos’ business or ability to obtain financing, and (vi) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.

Media Inquiries:

Jennifer Hauser, Executive Assistant to the CEO
Investor Relations Contact
[email protected]